Elevated serum β-synuclein predicts cognitive decline and progression to dementia

Area of Science:

• Neuroscience
• Biomarker Discovery
• Alzheimer's Disease Research

Background:

• Synaptic dysfunction is central to Alzheimer's disease (AD) pathogenesis.
• Beta (β)-synuclein, a brain phosphoprotein, is a potential biomarker for synaptic dysfunction.
• Its role in AD's longitudinal clinical progression requires further investigation.

Purpose of the Study:

• To investigate the association of serum β-synuclein levels with AD pathologies.
• To examine the relationship between serum β-synuclein and cognitive performance.
• To assess the link between serum β-synuclein and the risk of dementia progression.

Main Methods:

• Analysis of serum β-synuclein levels in 474 participants from the AD Neuroimaging Initiative cohort.
• Correlation of serum β-synuclein with cerebrospinal fluid (CSF) AD pathologies (tau, amyloid-β).
• Statistical modeling (linear regressions, mixed-effects, Cox models) to assess cognition and dementia risk.

Main Results:

• Elevated serum β-synuclein correlated with increased CSF phosphorylated tau and total tau, and decreased CSF amyloid-β (1-42).
• Higher serum β-synuclein predicted poorer baseline cognition and accelerated cognitive decline across multiple scales.
• Increased serum β-synuclein levels were associated with a higher risk of dementia progression over 84 months.

Conclusions:

• Serum β-synuclein shows promise as a biomarker for Alzheimer's disease progression and cognitive decline.
• Findings suggest serum β-synuclein may be an independent predictor of dementia risk.
• Further research is needed to validate its role in AD pathogenesis and clinical utility.